#JCLSpotlight: A text-based Health platform showed high interactivity & acceptability for tracking statin-associated muscle symptoms over time.
Read more from the study: https://ow.ly/ECuU50YEFyV
0
0
0
0
Hashtag
#JCLSpotlight
Advertisement · 728 × 90
#JCLSpotlight: Elevated Lp(a) was found in 8.3% of the general population & up to 23.9% in those with ASCVD. Adding Lp(a) as a risk enhancer improved risk reclassification beyond HellenicSCOREII+ in two Greek cohorts.
Read more: https://ow.ly/jXMT50YCr6E
0
0
0
0
#JCLSpotlight: Poor sleep quality is linked to unfavorable lipid profiles, especially elevated sdLDL-C levels. Treating sleep quality as a modifiable lifestyle factor may help reduce lipid abnormalities and prevent CVD.
Read more: https://ow.ly/vayN50YBKQB
0
0
0
0
#JCLSpotlight | #NationalTriglyceridesDay
Rare late-onset FCS case highlights:
▪️ Delayed diagnosis → pancreatic insufficiency and malnutrition
▪️ Statin and pioglitazone withdrawal → improved clinical status
▪️ Volanesorsen → 74% triglyceride reduction from baseline
Read: https://ow.ly/7W9g50YzLPX
0
0
0
0
#JCLSpotlight from the March Issue: Obese patients with diabetes and CAD who achieved LDL-C <1.8 mmol/L showed greater coronary atheroma regression than nonobese patients.
Read more: https://ow.ly/7V3F50YzlU1
0
0
0
0
#JCLSpotlight: Two pediatric cases of early death from FH, alongside a systematic review of childhood and adolescent FH-related deaths, reveal diagnostic delays and inadequate treatment as common contributing factors.
Read more about the findings: https://ow.ly/oG7L50YxyGv
0
0
0
0
#JCLSpotlight: A rare variant in SCARB1 — p.(Thr378Met) — impairs SR-B1-mediated HDL uptake and is associated with elevated HDL-C levels, supporting SCARB1 as a candidate gene for genetic screening in patients with dyslipidemia.
Read more: https://ow.ly/yPhX50YwXV1
2
1
0
0
#JCLSpotlight: The BALANCE study shows olezarsen 80 mg reduced all-cause inpatient service utilization and improved the experience of patients with FCS after just one year of treatment.
Read more: https://ow.ly/AICF50Yw3ea
1
1
0
0
The JCL February issue is live!📰
First in the #JCLSpotlight: A meta-analysis of 92 studies found carotid plaque in 23% of asymptomatic adults (18–65), rising from 5.2% (18–45) to 30.3% (50–65) and higher in men vs women.
Read more: https://ow.ly/qpxv50YqaC2
0
0
0
0
#JCLSpotlight: A BPA alert for patients with LDL-C ≥ 190 mg/dL increased statin use (39.4%→61.7%), reduced LDL-C by 84.1 mg/dL, and raised FH diagnoses (2.3%→6.0%). Electronic messaging may improve treatment and detection. #HeartMonth
Read more: https://ow.ly/cxPq50Yhatl
0
0
0
0
#JCLSpotlight: In a new analysis of the CLEAR Outcomes trial, adding lipid-modifying therapy after randomization did not impact the observed results of the trial.
Read more: https://ow.ly/Xi4P50YeBq2
0
0
0
0
#JCLSpotlight A pilot trial shows artichoke leaf extract reduced liver steatosis and size and improved body composition in patients with obesity and MASLD, while noting a significant transaminase increase.
🔗Read more: https://ow.ly/BXZA50Ye3e4
1
0
0
0
#JCLSpotlight: Elevated relative fat mass is strongly associated with a higher prevalence of sleep disorders in U.S. adults, highlighting adiposity as a modifiable factor in sleep health and prevention strategies.
Read more: https://ow.ly/HpRT50YbKoh
0
0
0
0
#JCLSpotlight: Lomitapide effectively and safely reduced TG levels in FCS patients with prior pancreatitis over a nearly 3-year follow-up period. Results were consistent with open-label trial data despite a lower median dose, with no new safety signals observed.
🔗https://ow.ly/F0B650Y8X43
0
0
0
0
#JCLSpotlight: New research shows men and women have distinct inflammatory responses during long-term evolocumab therapy, highlighting the importance of sex-specific considerations in CV risk management and treatment monitoring.
Read more: https://ow.ly/Fa8B50Y3Utv
0
0
0
0
#JCLSpotlight: New research shows PCSK9 inhibitors and inclisiran significantly reduce visit-to-visit LDL-C variability vs standard therapy. Lower LDL-C variability was linked to fewer CV events, highlighting lipid stability as a key treatment goal.
Read more: https://ow.ly/qLkI50Y0Gbh
0
1
0
0
The January JCL issue is live!📘
#JCLSpotlight: A pooled analysis of phase 3 ODYSSEY studies shows that in patients with ASCVD (without prior ACS or stroke), alirocumab significantly reduced LDL-C vs placebo or ezetimibe.
Read more: https://ow.ly/QZrQ50Y0eyy
0
1
0
0
#JCLSpotlight: High plasma Lp(a) is linked to increased IFN-γ–associated gene expression in classical monocytes and elevated CXCL10 in those without ASCVD, while chromatin accessibility remains unchanged across groups.
Read more: https://ow.ly/NENz50XKWcC
0
0
0
0
#JCLSpotlight: New data from the Balance study shows strong concordance between NAFCS Score ≥45 and a positive genetic diagnosis of FCS. The score can clinically support an FCS diagnosis when genetic testing isn’t available or is indeterminate.
Read more: https://ow.ly/7EBj50XKW2h
0
1
0
0
#JCLSpotlight: 2/3 of statin-intolerant patients report self-medication—often pain meds, vitamin D, electrolytes & omega-3s. None linked to lower LDL-C. Over half report negative statin messaging, highlighting the need for proactive guidance.
Read more: https://ow.ly/gcoj50XKVUj
0
0
0
0
#JCLSpotlight: Data from a phase 2b trial suggests evinacumab may help lower triglycerides in patients with sHTG and a history of sHTG-associated acute pancreatitis.
Learn more: ow.ly/h3wn50XHFVh
0
0
0
0
#JCLSpotlight: Current lipid-lowering therapies have only modest impact on Lp(a), but new RNA-targeted agents are showing promise. Pelacarsen—an antisense oligonucleotide—reduced Lp(a) by ≥80% in phase 2b and is now in multiple phase 3 trials.
Read more: ow.ly/T6Jy50XBZhz
2
0
0
0